申请人:Pfizer Inc.
公开号:US04654352A1
公开(公告)日:1987-03-31
Compounds of the formula: ##STR1## and pharmaceutically-acceptable acid addition salts thereof, wherein R.sup.1 is at the 3 or 4 position and is phenyl or phenyl substituted by halo, (C.sub.1 -C.sub.4)alkoxy, or (C.sub.2 -C.sub.5)alkoxycarbonyl; R.sup.2 is at the 2 or 7 position and is a group of the formula X(CH.sub.2).sub.n NR.sup.3 R.sup.4 where X is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; n is 1, 2, 3 or 4; and each of R.sup.3 and R.sup.4 is hydrogen or (C.sub.1 -C.sub.4)alkyl, or R.sup.3 and R.sup.4 together with the nitrogen atom to which they are attached form a 1-pyrrolidinyl or piperidino group; Y is hydrogen, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy or (C.sub.2 -C.sub.5)-alkoxycarbonyl at the 4, 5, 6 or 7 position; and wherein R.sup.2 is at the 2-position, R.sup.1 is at the 3- or 4-position, or alternatively when R.sup.2 is at the 7-position, R.sup.1 is at the 3-position; are useful for the treatment of diarrhea in humans and animals.
该公式化合物及其药学上可接受的酸盐包括以下成分:其中R.sup.1位于3或4位置,是苯基或被卤素、(C.sub.1 -C.sub.4)烷氧基或(C.sub.2 -C.sub.5)烷氧羰基取代的苯基;R.sup.2位于2或7位置,是具有X(CH.sub.2).sub.n NR.sup.3 R.sup.4式的基团,其中X为--CH.dbd.CH--或--(CH.sub.2).sub.2--;n为1、2、3或4;R.sup.3和R.sup.4中的每一个是氢或(C.sub.1 -C.sub.4)烷基,或者R.sup.3和R.sup.4连同它们连接的氮原子形成1-吡咯基或哌啶基;Y在4、5、6或7位置是氢、(C.sub.1 -C.sub.4)烷基、(C.sub.1 -C.sub.4)烷氧基或(C.sub.2 -C.sub.5)-烷氧羰基;其中R.sup.2位于2位置,R.sup.1位于3或4位置,或者当R.sup.2位于7位置时,R.sup.1位于3位置;适用于治疗人类和动物的腹泻。